Abstracts tagged "gout"

Abstract Number: 1031 • 2018 ACR/ARHP Annual Meeting
Orally Administered Cherry Juice Inhibits Localized Nfκb Activity and Histopathological Infiltrates in a Murine Model of Gout
Nicholas A. Young¹, Peter Harb², Ifeoma Okafor³, Caitlin Henry², Emily Schwarz², Kyle Jablonski⁴, Bianca Sandoval², Wael Jarjour⁵ and Naomi Schlesinger⁶, ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Rheumatology and Immunology, Columbus, OH, ³Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Department of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gout is caused by the inflammation induced from the precipitation of monosodium urate (MSU) crystals in joints and is the most common inflammatory arthritis…
Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Silvia Rollefstad¹, Till Uhlig^2,3, Lars Fridtjof Karoliussen³, Hilde B. Hammer⁴ and Anne Grete Semb⁵, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…
Abstract Number: 2254 • 2018 ACR/ARHP Annual Meeting
Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing
Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Pegylated uricases are promising therapies for the treatment of severe chronic gout, but are limited by their immunogenicity. We have previously shown that synthetic…
Abstract Number: 1124 • 2018 ACR/ARHP Annual Meeting
Epidemiological Characteristics of Inpatient Admissions for Acute Inflammatory Gout Arthropathy and Factors Affecting Length of Stay: A National Level Study
Vagishwari Murugesan and Jennifer Tran, Internal Medicine, Medstar Washington Hospital Center, Washington, DC
Background/Purpose:Gout is a common cause of inflammatory arthritis due to accumulation of monosodium urate crystals in joints, bones and soft tissues. The aim of the…
Abstract Number: 1294 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares
Rehan Azeem¹, Alan J. Kivitz², Earl Sands¹, Wesley DeHaan Ph.D.³, Lloyd Johnston³ and Takashi Kei Kishimoto³, ¹Selecta Biosciences, Inc, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Watertown, MA
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid tophi resolution. However, uricases are limited by induction of anti-drug antibodies…
Abstract Number: 2255 • 2018 ACR/ARHP Annual Meeting
Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database
Brian LaMoreaux¹, Megan Francis-Sedlak² and Robert J Holt², ¹Horizon Pharma USA, Inc, Lake Forest, IL, ²Horizon Pharma USA, Inc., Lake Forest, IL
Background/Purpose: Gout is a progressive systemic inflammatory disease that is widely prevalent, estimated to effect 3.9% or 8.3 million people of the United State (US)…
Abstract Number: 1119 • 2017 ACR/ARHP Annual Meeting
Uncontrolled Gout Patients with Higher Heart Failure Hospitalization Rates in US
Robert Morlock¹, Pierre Chevalier², An-Chen Fu³ and Douglas C.A. Taylor³, ¹YourCareChoice, Ann Arbor, MI, ²IMS Health, Zaventem, Belgium, ³Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis and is caused by elevated serum uric acid (sUA). Elevated sUA is associated with worsened…
Abstract Number: 2064 • 2017 ACR/ARHP Annual Meeting
The Nomenclature of Gout: A Content Analysis of Contemporary Medical Journals
David Bursill^1,2, William J. Taylor³, Robert Terkeltaub⁴ and Nicola Dalbeth⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²School of Medicine, University of Adelaide, Adelaide, Australia, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, VA San Diego Healthcare System, San Diego, CA, ⁵University of Auckland, Auckland, New Zealand
Background/Purpose: Gout has been recognized and described since antiquity. However, the terms used to describe the disease lack standardization. The aim of this study was…
Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Ted R. Mikuls¹, TC Cheetham², Gerald D. Levy³, Nazia Rashid⁴, Kimberly Low⁵, Brian W Coburn⁶, Kenneth Saag⁷, Lang Chen⁸ and Jeffrey R. Curtis⁹, ¹Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, ³Internal Medicine/Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Pharmacy Analytic Services, Kaiser Permanente Southern California, Downey, CA, ⁵Kaiser Permanente Southern California, Panorama City, CA, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…
Abstract Number: 1120 • 2017 ACR/ARHP Annual Meeting
Less Than Half of Patients Treated with High-Dose Allopurinol Reach Serum Uric Acid Target
Robert Morlock¹, Douglas C.A. Taylor² and Scott Baumgartner³, ¹YourCareChoice, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³drB Consulting, Spokane, WA
Background/Purpose: Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients…
Abstract Number: 2070 • 2017 ACR/ARHP Annual Meeting
Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout
Naomi Schlesinger¹, Puja Khanna², Anthony Yeo³ and Peter E. Lipsky⁴, ¹Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Horizon Pharma, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: A Delphi exercise reached consensus on a definition for gout remission that included serum uric acid (sUA) <6 mg/dL, no flares, resolution of all…
Abstract Number: 2896 • 2017 ACR/ARHP Annual Meeting
Human Cartilage Influences the Crystallization of Monosodium Urate; Understanding the Link between Gout and Osteoarthritis
Ashika Chhana¹, Bregina Pool², Ally Choi¹, Ryan Gao¹, Mark Zhu¹, Jillian Cornish², Jacob Munro³ and Nicola Dalbeth⁴, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Orthopaedics, Auckland City Hospital, Auckland, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: Monosodium urate (MSU) crystal deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. The aim of…
Abstract Number: 60 • 2017 ACR/ARHP Annual Meeting
Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy
Nicholas A. Young¹, Kyle Jablonski², Juhi Sharma¹, Evelyn Thomas¹, Brian Snoad¹, Jeffrey Hampton³, Wael Jarjour¹ and Naomi Schlesinger⁴, ¹Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Little is known regarding the potential benefits of exercise on managing acute gout. Consequently, recent clinical practice guidelines released by the American College of…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 2071 • 2017 ACR/ARHP Annual Meeting
A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property
Johji Nomura¹, Yoshimasa Takahashi², Kumiko Aoki², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: Hyperuricemia, abnormally elevated level of serum uric acid, is associated with gout as well as other diseases including metabolic syndrome, hypertension, diabetic kidney disease.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].